EIT Health Funding for UK Companies: Comparing the 2026 Calls

EIT Health is the European Institute of Innovation and Technology's health-focused community, and it funds very differently to Innovate UK: expect cross-border consortia, co-funding requirements, and application platforms that snap shut for months at a time between cycles. If you're a UK health-tech company trying to work out whether it's worth the effort, the short answer is that it depends heavily on how far along you already are, and right now, in late September 2026, the 2026 round has just closed.

What EIT Health actually is

EIT Health was set up in 2015 as a Knowledge and Innovation Community (KIC) of the European Institute of Innovation and Technology, an EU body, and it is funded through the Horizon Europe framework programme. It connects roughly 130 partner organisations across business, research, education and health service delivery (EIT Health, eithealth.eu, accessed 25 September 2026). That's the "Knowledge Triangle" you'll see referenced throughout its call documents: the EIT's founding principle that innovation moves faster when industry, research and education sit in the same consortium rather than working in isolation (European Institute of Innovation and Technology, eit.europa.eu, accessed 25 September 2026).

The practical consequence is that most EIT Health funding calls require a consortium, not a single applicant. That's a real departure from an Innovate UK smart grant, and it's the first thing to check before you invest time in a proposal.

UK eligibility is more straightforward than you might expect post-Brexit. The UK has been formally associated to Horizon Europe since January 2024 and remains associated as of 2026, which makes UK entities eligible "associated country" participants for standard Horizon Europe calls, EIT Health's included (UK Research and Innovation, ukri.org, accessed 25 September 2026). UK organisations can participate in, and in some calls lead, EIT Health consortia on the same footing as an EU member state applicant.

The three 2026 calls, compared

EIT Health ran several funding instruments through 2026. Three are the ones most likely to come up if you're a health-tech SME weighing this funder: the Innovation Uptake Call, the Transformative Healthcare Instrument, and the Innovation Validation Call. Each targets a different stage of maturity, and the funding amounts differ accordingly.

(Figures and dates: EIT Health, eithealth.eu/opportunity/innovation-uptake, /transformative-healthcare-instrument and /innovation-validation, all accessed 25 September 2026.)

Innovation Maturity Level is EIT Health's own maturity scale, not the nine-point Technology Readiness Level scale UK funders use, so don't assume the numbers map directly. If you're used to thinking in TRL terms for an Innovate UK application, our guide to technology readiness levels is a useful reference point for the underlying logic, even though the scale itself is different here.

The eligibility bar is higher than it first appears

Read past the headline funding figures and each call has a gate that rules out a lot of otherwise-strong applicants. The Transformative Healthcare Instrument requires you to have already closed at least €2,000,000 in equity investment within the preceding 36 months, with at least one new investor in that round, plus a minimum of four full-time-equivalent employees (EIT Health, eithealth.eu, accessed 25 September 2026). That's not a call for a pre-seed spinout; it's aimed at a company that has already proven it can raise.

The Innovation Uptake Call and Innovation Validation Call both require a consortium of at least two independent legal entities from different Horizon Europe countries, spanning at least two sides of the Knowledge Triangle, led by a "Commercialising Entity" responsible for getting the product to market (EIT Health, eithealth.eu, accessed 25 September 2026). If you don't already have a research or education partner in another eligible country, building that relationship from scratch is itself a months-long piece of work, well before you start drafting the application.

None of this makes EIT Health a bad option. It makes it a poor fit for a company still validating its technology on a single UK site with no international partners lined up, and a strong fit for a company that already has CE marking, clinical evidence, or a recent funding round behind it and is now trying to scale across European markets.

Where the 2026 round stands right now

As of 25 September 2026, all three calls above are closed. The Innovation Validation Call closed on 6 May 2026, and both the Innovation Uptake Call and the Transformative Healthcare Instrument closed on 16 September 2026 (EIT Health, eithealth.eu/get-involved/new-call-opportunities, accessed 25 September 2026). If you've found this page while searching for an open call to apply to this week, none of these three are it.

EIT Health has run equivalent instruments in previous cycles, and it states that "additional calls will be launched throughout 2026 and 2027 covering a range of topics" (EIT Health, eithealth.eu, accessed 25 September 2026), but it hasn't published exact 2027 dates or confirmed the next round will mirror this one exactly. The realistic plan, if you're a genuine fit, is to treat this closed round as the template: get your consortium partners identified, your evidence pack together, and your equity or clinical-validation position squared away, so you're ready to move fast when the next equivalent call opens rather than starting cold.

Should a UK health-tech company bother?

If you're pre-clinical, haven't raised meaningfully yet, or don't have an international partner, the honest answer is not this cycle. The upfront cost of assembling a compliant consortium and clearing the maturity bar will outweigh what you'd get from applying to a call you're unlikely to win. That time is better spent on a funder whose eligibility matches where you actually are, whether that's an earlier-stage Innovate UK smart grant or an NIHR i4i scheme.

If you already have CE marking, real clinical evidence, or a recent equity round and you're specifically trying to expand into European markets, EIT Health is one of the few UK-accessible funders built for exactly that step, and the co-funding rate (up to 50%, rather than needing to find the balance of costs entirely yourself as with some UK schemes) is genuinely competitive.

How GrantHero helps you prepare for the next cycle

GrantHero tracks competitions across the funders that matter for UK innovators, including EIT Health, alongside Innovate UK, EIC, NIHR, DASA and Eureka, and scores how well your company profile fits each one before you commit time to an application. For a funder like EIT Health, where the eligibility gate (the equity threshold, the maturity level, the consortium requirement) is what actually decides whether an application is worth writing, an honest fit check before you start is the most useful thing we can do for you. The platform is free to use for matching and eligibility checks, with paid support for drafting and expert review once you've found a competition worth pursuing; see current pricing at granthero.io/pricing. You can also see how we support UK health and life sciences companies more broadly on our healthcare funding page.